Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
J Thorac Oncol
; 19(4): 650-652, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38340108
ABSTRACT
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pirimidinas
/
Acrilamidas
/
Carcinoma de Pulmón de Células no Pequeñas
/
Indoles
/
Neoplasias Pulmonares
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
J Thorac Oncol
/
J. thorac. oncol
/
Journal of thoracic oncology
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos